Edition:
United States

Five Prime Therapeutics Inc (FPRX.OQ)

FPRX.OQ on NASDAQ Stock Exchange Global Select Market

13.80USD
24 Sep 2018
Change (% chg)

-- (--)
Prev Close
$13.80
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
126,243
52-wk High
$48.74
52-wk Low
$12.52

Select another date:

Wed, May 30 2018

BRIEF-Five Prime Therapeutics Announces Collaboration With Roche

* FIVE PRIME THERAPEUTICS ANNOUNCES COLLABORATION WITH ROCHE TO DEVELOP COMPANION DIAGNOSTICS FOR TARGETED IMMUNO-ONCOLOGY INVESTIGATIONAL DRUG CANDIDATES

BRIEF-Five Prime Therapeutics Appoints Bryan Irving As Chief Scientific Officer

* FIVE PRIME THERAPEUTICS APPOINTS BRYAN IRVING, PH.D., AS CHIEF SCIENTIFIC OFFICER Source text for Eikon: Further company coverage:

BRIEF-Five Prime Therapeutics Reports Q1 Loss Per Share $0.63

* FIVE PRIME THERAPEUTICS ANNOUNCES FIRST QUARTER 2018 FINANCIAL RESULTS

BRIEF-Five Prime Therapeutics Appointed Linda Rubinstein As Interim CFO

* FIVE PRIME THERAPEUTICS INC - ON APRIL 13 APPOINTED LINDA RUBINSTEIN AS INTERIM CHIEF FINANCIAL OFFICER - SEC FILING

BRIEF-Five Prime Therapeutics To Close Bladder Cancer Cohort Of Its Phase 1 FPA144-001 Trial

* TO CLOSE BLADDER CANCER COHORT OF PHASE 1 TRIAL EVALUATING BEMARITUZUMAB TREATING PATIENTS WHOSE TUMORS OVEREXPRESS FGFR2B PROTEIN

BRIEF-Personal Genome Diagnostics enteres into a collaboration with Five Prime Therapeutics

* CO INTENDS TO SUBMIT ASSAY FOR REGULATORY APPROVAL, COMMERCIALIZE IN U.S., EUROPE, JAPAN, CHINA, OTHER COUNTRIES

BRIEF-Five Prime Therapeutics Starts Patient Dosing In Phase 1 Trial In Antibody Study

* FIVE PRIME THERAPEUTICS INITIATES PATIENT DOSING IN PHASE 1 TRIAL OF NOVEL FIRST-IN-CLASS B7-H4 ANTIBODY FPA150 Source text for Eikon: Further company coverage: (Bengaluru Newsroom: +1 646 223 8780)

Select another date: